Seres Therapeutics
MCRB
33 hedge funds and large institutions have $25.4M invested in Seres Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 37 closing their positions.
783% more call options, than puts
Call options by funds: $2.23M | Put options by funds: $253K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9.11% less ownership
Funds ownership: 35.27% → 26.17% (-9.1%)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
41% less capital invested
Capital invested by funds: $43.1M → $25.4M (-$17.7M)
48% less funds holding
Funds holding: 63 → 33 (-30)
78% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$804K |
| 2 |
Vontobel Holding
Zurich,
Switzerland
|
+$229K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$197K |
| 4 |
Squarepoint
New York
|
+$184K |
| 5 |
BlackRock
New York
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.27M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$574K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$213K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$110K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$95.6K |
MCRB Hedge Fund Activity: Q2 2025 in Review
33 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2025, worth a combined $25.4M — down 41% from $43.1M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of MCRB and 8 opened new positions — a net loss of 29 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $804K. The largest seller was Fidelity Investments, cutting an estimated $7.27M.
- 33 institutional investors held Seres Therapeutics (MCRB) as of Q2 2025, down from 63 in Q1 2025.
- Funds reported $25.4M of Seres Therapeutics stock for Q2 2025, down 41% quarter-over-quarter.
- 8 funds opened new Seres Therapeutics positions in Q2 2025 and 37 closed out, a net change of -29 holders.
- The largest Seres Therapeutics buyer in Q2 2025 was Marshall Wace, an estimated $804K added.
- The largest Seres Therapeutics seller in Q2 2025 was Fidelity Investments, an estimated $7.27M sold.
Based on aggregated 13F filings for Q2 2025.